Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Follow-up of Unruptured Intracranial Aneurysms With Ultra-High Field 7 Tesla MRI

17 novembre 2026 aggiornato da: Insel Gruppe AG, University Hospital Bern

Approximately 275'000 people in Switzerland harbor an unruptured intracranial aneurysm (UIA). Rupture leads to subarachnoid hemorrhage, which is associated with high morbidity and mortality and causes 25% of all cerebrovascular-related deaths. UIAs cause a relevant healthcare burden, which is increasing due to the extensive use of neuroimaging. They pose a challenge to both patients and physicians: Patients have to live with the diagnosis of an aneurysm that can cause a rupture with severe consequences. Physicians have to judge whether the risks of preventive occlusion are lower than those of natural history. Management consists of observation with follow-up imaging or preventive aneurysm occlusion weighing up the risk of natural history against the risk of treatment. Estimating rupture risks of UIAs in an individual patient is the crucial step in clinical decision-making.

Older studies suggested that small UIA (<7mm) have a negligible rupture risk and most incidental UIAs are small. Following this logic, most patients with UIA do not require preventive treatment. However, 70-80% of patients presenting with subarachnoid hemorrhage carry aneurysms <7 mm in size, leading to the so-called "aneurysm-rupture paradox". Newer evidence shows that UIAs have a heterogenous natural history: They can either form and remain stable for a long time or present an unstable course, entertained by wall inflammation, leading to aneurysm growth, and ultimately rupture.

The main clinical challenge in UIA is to correctly identify aneurysms that have an unstable course out of the increasing amount of incidentally detected UIAs and offer preventive treatment to these selected patients. Growth during follow-up, irregular aneurysm shape, hypertension, and smoking are currently used as main surrogate parameters to predict an unstable UIA.

Ultra-high field 7 Tesla MRI (UHF 7T MRI) has become clinically available as a new imaging modality. Due to the higher field strength, UHF 7T MRI enables imaging with an increased signal-to-noise ratio resulting in significantly improved vessel wall imaging and spatial resolution to detect AWE and morphological changes with high precision. With these properties, UHF 7T MRI has the potential to overcome current limitations of vessel wall imaging in 3T MRI by providing information on AWE with increased specificity omitting the high false positive rates that make AWE as a biomarker in 3T MRI not useful.

After obtaining the signed informed consent and inclusion in the study, demographics will be assessed. The 3T MRI and 7T UHF MRI follow-up examination will be scheduled as a next step, and the appointment will be communicated to the participant. The timing of the 3T + 7T UHF MRI examination is not determined by the date of enrolment but by the timing of the baseline examination and must be no later than 12±1 months after that.

The exam will take place at the Translational Imaging center in Sitem-insel. Before the MRI examination, participants are asked to provide information on risk factors for UIA and medication history via a questionnaire. For the MRI examination, a 3 T scanner will be used with a standard head coil provided by the the MR-vendor and a 7 T whole-body MRI scanner equipped with a 1-channel transmit and 32-channel receive head coil. The 7T protocoll will comprose arterial ToF angiography and vessel wall imaging sequences (T1 SPACE and T1 SE dark blood). The acquisition time is approximately 44 minutes. The 3T examination will be performed according to the clinical standard protocol. After the examination, participants can go directly home and no further examinations will be performed at this appointment.

According to the standard of care at our institutions, all follow-up examinations of patients with UIA, who have been assigned to observation with MRI, will be discussed at the interdisciplinary aneurysm board. Within 4-8 weeks after the 3T + 7T UHF MRI examination, a chart review of the board decision and outpatient visits will be performed to determine whether management changed from observation to intervention. Furthermore, the occurrence of subarachnoid hemorrhage during the study period will be recorded if applicable.

Panoramica dello studio

Descrizione dettagliata

Approximately 275'000 people in Switzerland harbor an unruptured intracranial aneurysm (UIA). Rupture leads to subarachnoid hemorrhage, which is associated with high morbidity and mortality and causes 25% of all cerebrovascular-related deaths. UIAs cause a relevant healthcare burden, which is increasing due to the extensive use of neuroimaging. They pose a challenge to both patients and physicians: Patients have to live with the diagnosis of an aneurysm that can cause a rupture with severe consequences. Physicians have to judge whether the risks of preventive occlusion are lower than those of natural history. Management consists of observation with follow-up imaging or preventive aneurysm occlusion weighing up the risk of natural history against the risk of treatment. Estimating rupture risks of UIAs in an individual patient is the crucial step in clinical decision-making.

Older studies suggested that small UIA (<7mm) have a negligible rupture risk and most incidental UIAs are small. Following this logic, most patients with UIA do not require preventive treatment. However, 70-80% of patients presenting with subarachnoid hemorrhage carry aneurysms <7 mm in size, leading to the so-called "aneurysm-rupture paradox". Newer evidence shows that UIAs have a heterogenous natural history: They can either form and remain stable for a long time or present an unstable course, entertained by wall inflammation, leading to aneurysm growth, and ultimately rupture.

The main clinical challenge in UIA is to correctly identify aneurysms that have an unstable course out of the increasing amount of incidentally detected UIAs and offer preventive treatment to these selected patients. Growth during follow-up, irregular aneurysm shape, hypertension, and smoking are currently used as main surrogate parameters to predict an unstable UIA. However, these parameters are only indirect since they are either consequences of wall inflammation (growth, irregular shape) or are risk factors that increase the probability of it (smoking, hypertension).

In contrast to this, aneurysm wall enhancement (AWE) is a possible direct biomarker that can visualize wall inflammation and, therefore, aneurysm instability. Studies investigating AWE and aneurysm instability showed a reasonably high sensitivity for prediction of aneurysm growth but are limited by low specificity and a high false-positive rate since AWE was present in 30-40% of aneurysms that were stable during follow-up. Therefore use of AWE as an indicator for aneurysm instability has not yet made the critical step as a reliable biomarker in the decision-making process, despite its high potential. Consequently, recent UIA guidelines from the European Stroke Organization highly recommend further clinical studies on AWE.

Ultra-high field 7 Tesla MRI (UHF 7T MRI) has become clinically available as a new imaging modality. Due to the higher field strength, UHF 7T MRI enables imaging with an increased signal-to-noise ratio resulting in significantly improved vessel wall imaging and spatial resolution to detect AWE and morphological changes with high precision. With these properties, UHF 7T MRI has the potential to overcome current limitations of vessel wall imaging in 3T MRI by providing information on AWE with increased specificity omitting the high false positive rates that make AWE as a biomarker in 3T MRI not useful. However, data analyzing AWE with increased precision in UHF 7T MRI in a large cohort are missing.

The Translation Imaging Center Bern (TIC) at sitem-insel provides a unique imaging infrastructure in Switzerland and worldwide with a clinically approved latest generation UHF 7T MRI system and 3T MRI allowing direct comparing of findings at 3T and 7T.

After obtaining the signed informed consent and inclusion in the study, demographics will be assessed. The 3T MRI and 7T UHF MRI follow-up examination will be scheduled as a next step, and the appointment will be communicated to the participant. The timing of the 3T + 7T UHF MRI examination is not determined by the date of enrolment but by the timing of the baseline examination and must be no later than 12±1 months after that. Before the MRI is performed, a urine pregnancy test will be performed for all woman with childbearing potential.

The exam will take place at the Translational Imaging center in Sitem-insel. Before the MRI examination, participants are asked to provide information on risk factors for UIA and medication history via a questionnaire. For the MRI examination, a 3 T scanner (MAGNETOM Prisma, Siemens Healthcare) will be used with a standard head coil provided by the the MR-vendor and a 7 T whole-body MRI scanner (MAGNETOM Terra, clinical mode, Siemens Healthcare, Erlangen, Germany) equipped with a 1-channel transmit and 32-channel receive head coil (Nova Medical, Wilmington, MA, USA). Only CE approved sequences will be accuired. The 7T protocoll will comprose arterial ToF angiography and vessel wall imaging sequences (T1 SPACE and T1 SE dark blood). The acquisition time is approximately 44 minutes. The 3T examination will be performed according to the clinical standard protocoll. After the examination, participants can go directly home and no further examinations will be performed at this appointment.

According to the standard of care at our institutions, all follow-up examinations of patients with UIA, who have been assigned to observation with MRI, will be discussed at the interdisciplinary aneurysm board. Within 4-8 weeks after the 3T + 7T UHF MRI examination, a chart review of the board decision and outpatient visits will be performed to determine whether management changed from observation to intervention. Furthermore, the occurrence of subarachnoid hemorrhage during the study period will be recorded if applicable.

Tipo di studio

Interventistico

Iscrizione (Stimato)

100

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Bern, Svizzera, 3010
        • Reclutamento
        • Inselspital Bern, Department of Neurosurgery
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Johannes Goldberg, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients harboring an untreated UIA ≥ 3mm that was assigned to observation with 3T MRI follow-up after 12 (±1) months by the Inselspital interdisciplinary aneurysm board
  • Available 3T MRI including TOF and vessel wall imaging with gadolinium contrast at baseline
  • Age ≥ 18 years

Exclusion Criteria:

  • Contraindications to undergo UHF 7T MRI
  • Contraindications for gadolinium contrast agent
  • Fusiform, mycotic, dissecting, traumatic, clinoidal, carotid-cave or cavernous aneurysms
  • Partially or completely thrombosed aneurysms
  • Flow-related aneurysms in the context of an arteriovenous shunt
  • Family history of polycystic kidney disease, Ehlers-Danlos syndrome, Marfan's syndrome, fibromuscular dysplasia, Moya-Moya disease, or Loeys-Dietz syndrome
  • Pregnancy (in case of childbearing potential)
  • Pacemaker implantation

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Diagnostico
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: 3T and 7T UHF MRI

aneurysm wall enhancement, aneurysm growth, and changes in aneurysm morphology in a simoultaneous 3T (standard clinical follow-up) and UHF 7T MRI

After obtaining the signed informed consent and inclusion in the study, demographics will be assessed. The timing of the 3T + 7T UHF MRI examination is not determined by the date of enrolment but by the timing of the baseline examination and must be no later than 12±1 months after that.

The exam will take place at the Translational Imaging center in Sitem-insel. Before the MRI examination, participants are asked to provide information on risk factors for UIA and medication history via a questionnaire. For the MRI examination, we will use a 3 T scanner with a standard head coil provided by the the MR-vendor and a 7 T whole-body MRI scanner equipped with a 1-channel transmit and 32-channel receive head coil. The 7T protocoll will comprose arterial ToF angiography and vessel wall imaging sequences. Within 4-8 weeks after the 3T + 7T UHF MRI examination, a chart review of the booard decision and outpatient visits will be performed to determine whether management changed from observation.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Correlation between aneurysm wall enhancement (AWE) characteristics and aneurysm growth or change of morphology compared to standard follow-up
Lasso di tempo: 12 months after baseline MRI

We will assess AWE, aneurysm growth, and changes in aneurysm morphology in a simoultaneous 3T (standard clinical follow-up) and UHF 7T MRI after 12±1 months of follow-up. AWE is categorized as none, focal, circumferential <1mm, or circumferential >1mm. Aneurysm growth is defined as an increase in diameter in any direction by ≥1mm and categorized as absent or present. Morphological change is defined as any new occurrence of irregular shape (such as lobulation, blep, aneurysm wall protrusions) and is categorized as absent or present.

12 months after baseline MRI

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
aneurysm wall enhancement in UHF 7T MRI and standard clinical follow-up with 3T MRI after 12 months of Follow UP
Lasso di tempo: 12 months Follow UP
12 months Follow UP
aneurysm growth in UHF 7T MRI and standard clinical follow-up with 3T MRI after 12 months of follow-up.
Lasso di tempo: 12 months Follow UP
12 months Follow UP
changed morphology in UHF 7T MRI and standard clinical follow-up with 3T MRI after 12 months of follow-up
Lasso di tempo: 12 months Follow UP
12 months Follow UP
aneurysm wall enhancement
Lasso di tempo: baseline
baseline
aneurysm size
Lasso di tempo: baseline
baseline
aneurysm morphology
Lasso di tempo: baseline
baseline
Risk factors
Lasso di tempo: baseline
baseline
medications
Lasso di tempo: baseline
baseline
Focal aneurysm wall enhancement patterns in UHT 7T MRI with 3D mapping of the aneurysm dome
Lasso di tempo: 12 months Follow UP
12 months Follow UP
Incidence of subarachnoid hemorrhage during follow-up
Lasso di tempo: 12 months Follow UP
12 months Follow UP
Incidence of aneurysm growth during follow-up
Lasso di tempo: 12 months Follow UP
12 months Follow UP
Change of management from observation toward intervention after the follow-up visit
Lasso di tempo: 12 months Follow UP
12 months Follow UP
Radiomics of the aneurysm dome
Lasso di tempo: 12 months Follow UP
12 months Follow UP

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

18 dicembre 2024

Completamento primario (Stimato)

31 agosto 2028

Completamento dello studio (Stimato)

28 febbraio 2029

Date di iscrizione allo studio

Primo inviato

10 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

17 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi